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ABSTRACT

Salem, Salma. M.S., Purdue University, December 2016. Innovative Novel Imuno
Therapies for the Treatment of Glioblastoma Multiforme. Major Professor: Kari Clase.

Glioblastoma Multiforme GBM is a very aggressive type of malignant brain tumors
that affects SHRSOHV¶OLYHV The diffusive, infiltrative, and metastatic behaviour of GBM is
the major reason for the disease recurrence. The morphological and immunohistological
characteristics of Central Nervous System (CNS) tumors including GBM are
heterogeneous. GBM is either primary (de novo) or secondary to low-grade
astrocytomas.
Current treatment options include surgery, radiotherapy, and temozolomide
chemotherapy have not achieved any improvement in success rates over the past decades.
The survival time reached by GBM patients was approximately 12 months only after
being treated with radiotherapy alone without temozolomide. However, the median
survival time has been estimated as 14.6 months in patients who received the combined
treatment of radiotherapy and chemotherapy with temozolomide. Temozolomide is an
alkylating agent that exhibit antitumor activity and prescribed as a single agent for the
treatment of recurrent glioma. It diminishes the O6-methylguanine-DNA
methyltransferase (MGMT) enzyme, which is responsible for DNA repair. GBM

xii
Patientswith activated O6-alkylguanine transferase AGT enzyme were reported to
develop resistant to temozolomide.
Targeted therapies are RWKHURSWLRQVIRU*%0SDWLHQWV%HYDFL]XPDEEORFNVWKH
HIIHFWRI+XPDQ9DVFXODU(QGRWKHOLDO*URZWK)DFWRU 9(*) DQGLQKLELWVWXPRUYDVFXODU
JURZWK5HJXODWRU\FRQFHUQVDERXWFOLQLFDOWULDOVFRQGXFWHGZLWKEHYDFL]XPDELQFOXGLQJ
WULDOGHVLJQSUREOHPVKDYHEHHQUDLVHG
Targeting the immune system will identify successful treatments for GBM with
significant clinical benefits. The use of active immunotherapy to increase the native
immune response or passive immunotherapy to target the tumor cells in GBM patients
are under investigation. Dendritic Cells DCs are the most potent antigen presenting APCs
in the immune system. DCs have the ability to stimulate the native T cells and induce
primary immune responses and peripheral immunological tolerance through capturing,
processing neoantigens, which are formed and released by oncogenesis, and presenting
the captured antigens on Histocompatibility Complex I and II (MHCI and MHCII)
molecules to T cells. After that T cell responses against the cancer-specific antigens are
primed and activated. T cells infiltrate the tumor bed, specifically recognize, bind to, and
kill their target cancer cell. The sources of antigen that have been used in DC
immunotherapy include exogenous MHC-restricted peptides, acid-eluted tumor peptides,
tumor RNA and cDNA, viral vectors, apoptotic tumor cells, tumor cell lysate, and whole
glioma cells. Clinical trials showed that treating GBM patients with surgery, TMZ, and
Dendritic Cell DC vaccines was safe and achieved meaningful clinical outcomes.
The purpose of this research is to investigate the clinical outcomes of DC vaccines
for the treatment of GBM patients through the published data on the rapidly growing field
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of clinical trials. Furthermore, this research focuses on investigating immune responses
that are related to the most beneficial clinical outcomes to identify new prognostic
biomarkers and therapeutic targets.
7KLVUHVHDUFK¶Vfindings have showed evidence that many different variables were
associated with different cancer specific immune responses and clinical outcomes. These
variables include loading DC vaccines with tumor material or Tumor Associated
Antigens TAAs, and combining DC vaccines with different pre and post vaccination
treatment strategies. DC vaccine pulsed with specific synthetic antigens have achieved
more beneficial clinical outcome than DC vaccines loaded with tumor material. Prevaccination treatment strategy with TMZ has increased the Overall Survival and the
Progression Free Survival of GBM patients. Although, pre-vaccination treatment strategy
with TMZ+RT has achieved significant improvement of Overall Survival, there was no
improvement of the Progression Free Survival associated with the strategy.
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CHAPTER 1. INTRODUCTION

This chapter introduces the overview of Glioblastoma Multiforme (GBM) research
work. This chapter provides a statement of the problem in GBM cancer studies, research
question, scope, significance, definitions of key terms, assumptions, limitations, and
delimitations of this research study.

1.1

Statement of the Problem

Glioblastoma Multiforme GBM is a very aggressive type of malignant brain tumors
WKDWDIIHFWVSHRSOHV¶OLYHV*%0KDVWKHDELOLW\WRHVFDSHLPPXQHV\VWHPVXUYHLOODQFH
and causes major mutations in cell signaling and growth. Current treatment options
including surgery, radiotherapy, and temozolomide chemotherapy have not achieved any
improvement in success rates over the past decades. Targeting the immune system will
identify successful treatments for GBM with significant clinical benefits. The purpose of
this research is to investigate innovative immunotherapies for GBM by using data
published on the rapidly growing field of clinical trials.

1.2

Research Question

Do innovative immunotherapies for Glioblastoma Multiforme have the ability to
LQFUHDVHWKHDFWLYDWLRQRISDWLHQWV¶LPPXQHsystem and successfully treat the disease?
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1.3

Scope

The scope of this research is to investigate the innovative immunotherapies for the
treatment of Glioblastoma Multiforme (GBM) using available published literature and
various data analysis techniques. This study is conducted to explore the clinical outcomes
of Dendritic Cell vaccines; which are currently under investigation for the treatment of
GBM. The study is exploring the efficiency of the treatment combination of
immunotherapy, chemotherapy, following surgical resection of the tumor mass.
Furthermore, the study focuses on identifying immune responses, prognostic biomarkers,
and new therapeutic targets for GBM.

1.4

Significance

The treatment options of Glioblastoma Multiforme, including surgical removal,
radiation therapy, and cytotoxic chemotherapy, are very aggressive as well as they do not
achieve any improvement in the disease state. This research will use data published on
the rapidly growing field of clinical trials to provide in depth knowledge about GBM and
host factors that are related to immune system interactions.
The research investigates innovative immunotherapies, which present a potential
solution to treat Glioblastoma Multiforme. The result of this work will be a seed for
future research on identifying a new treatment with significant clinical benefits that is
capable of handling the obstacles that are facing the development of glioblastoma
immunotherapies.
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1.5

Definitions of Key Terms

Apoptosis is a genetically encoded cell death program which is well known by the
corresponding morphologic and biochemical changes (Fisher, 1994).
Biomarkers are measureable quantities of biologic homeostasis that are used to
differentiate between normal and abnormal and can be detected using recent
technological advances (Dalton & Friend, 2006).
Brain metastases are brain tumors that originate in specific tissue of origin outside the
brain and metastasize to the brain which resemble more than 50% of all brain
tumors in adults (Jacobs et al., 2009).
Carcinogen is a chemical, physical or viral stimuli which directly induces cancer by
formation of DNA adducts and initiation of various genetic mutations
(Higginson, 1987; Herbst, Heymach, & Lippman, 2008).
CD25+ CD4+ are suppressor Tregs lymphocytes which make the immunity system
unresponsive to self-constituents, establish what is known as self-tolerance, and
maintain a negative control of pathological and physiological immune responses.
(Sakaguchi, 2004).
Dendritic cells (DCs) are antigen-presenting cells, which act by capturing and
transferring information from the surrounding environment to the cells of the
adaptive immune system. They can induce primary immune responses,
immunological tolerance, and regulate T cell±mediated immune response
(Banchereau et al., 2000).
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Immune system is the body system, which recognize foreign invaders and eliminate
them. It has the ability to distinguish between self- and non-self-constituents (or
antigens) (Thomas, Ernstoff, & Fadul, 2012). The immune system includes two
major branches: the innate and the adaptive immune systems (Kanaly, Ding,
Heimberger, & Sampson, 2010).
Oncogene is mutated gene which is resulted from different carcinogens and causes
intensive cell growth that proliferates into cancer cells (Herbst et al., 2008).
Temozolomide (TMZ) is DNA alkylating agent which exhibits antitumor activity and is
used for the treatment of Glioblastoma Multiforme (Stupp et al., 2005).

1.6

Assumptions

The assumptions of this thesis will include:


The sources of data are trusted.



Data analysis will be accurate and no data will be missed.

1.7

Limitations

The following limitations are inherent to the pursuit of this study:
x

The research will investigate the innovative dendritic cell vaccines for the
treatment of Glioblastoma Multiforme (GBM).

1.8

Delimitations

The following delimitations are inherent to the pursuit of this study:
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x

This study will not investigate the efficacy of the chemotherapy or the
radiotherapy treatments.

x

This study will not investigate the adaptive immunotherapies.
1.9

Summary

This chapter has provided an overview of the research study, including statement of
purpose, research question, scope, and significance, definitions of key terms,
assumptions, limitations, and delimitations.
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CHAPTER 2. LITERATURE REVIEW

This chapter presents an overview of Glioblastoma Multiforme (GBM),
Epidemiology, Metastases, cancer stem cell hypothesis, treatment options ³Radiotherapy,
%HYDFL]XPDE, and 7HPR]RORPLGH´, immune reactions in healthy brain and in
Glioblastoma patients, immunotherapy for the treatment of GBM, adoptive
immunotherapy, active immunotherapy, and nanotechnology in immunotherapy for the
treatment of GBM. It also introduces DC development, diversification, maturation, and
function, tumor associated antigens TAA, and end points and evidences of therapeutic
activity.

2.1

Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is a brain tumor with severe manifestations of
anaplasia and dedifferentiation of glia, which is representing about 50 % of all gliomas.
Glioblastoma is the most aggressive, complex, and common human brain tumor type,
which is known as grade four gliomas (Holland, 2000). Morphological and
immunological features show that the proliferation of Glioblastoma is accompanied by
immunological reaction against tumor-specific antibodies. It is the most malignant
primary intracranial neoplasm, which is identified by a gross and microscopic
morphology and affects mostly the older age populations. The disease can rarely affect
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ages under 40 years, although the peak age incidence lies between 48 and 55 years
(Jellinger, 1978).
CNS tumors such as Glioblastoma Multiforme are caused by genetic mutation
that results in a progressive neoplastic transformation of differentiated cells (Jellinger,
1978). The genetic mutation is characterized by several deletions, amplifications, and
point mutations that is followed by activation of signal transduction pathways, inhibition
of tyrosine kinase receptors, and disturbance in cell-cycle arrest pathways either by
INK4a-ARF gene loss or tumor suppressor p53 gene mutations (Holland, 2000).

2.2

Epidemiology

Central nervous system (CNS) primary tumors are affecting approximately 18.71
per 100,000 persons per year (States & others, 2010). Primary brain tumors are the main
cause of deaths in cancer patients and it represents about 2.3 % of deaths in cancer
SDWLHQWVLQ(XURSHDQG1RUWK$PHULFD &DQDGLDQ&DQFHU6RFLHW\¶V6WHHULQJ&RPPLWWHH
2010).
Glioma is the most common primary brain tumor with the incidence percent of 32
% of CNS tumors and 80 % of malignant CNS tumors as shown in Figure. 2.1 (Agnihotri
et al., 2013).
Glioblastomas are the most malignant glioma and the main type of astrocytoma
with an incidence percent of about 54 % of the astrocytic tumors. The incidence ratio of
Glioblastomas is 1.58:1 in men and women and 2:1 in Caucasians and AfricanAmericans respectively (States & others, 2010). Malignant gliomas are thought to be
related to family history in about 5 % of patients who usually experience a rare genetic
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syndrome such as neurofibromatosis types 1 and 2, and Li-Fraumeni syndrome (Farrell &
Plotkin, 2007).
2.3

Metastases

Metastasis is an invasive property that arises from interactions between cancer
cells and their microenvironment. This action is mostly due to the loss of the cell-cell
adhesion that is controlled by E-cadherin. The inactivation of E-cadherin originates from
inactive protein, gene silencing or the overexpression of the growth factor receptors.
There are also a number of genes which are responsible for genetic and epigenetic
mutations in cancer cells and are supported by micro environmental changes to initiate
metastatic behaviour of tumors (Chiang & Massagué, 2008). These genes are divided into
three groups: initiation, progression, and virulence genes (Nguyen & Massagué, 2007).
Genes that are responsible for the progression of metastasis make the cancer cell capable
of traveling successfully between different points until it reaches the distant site that is
identified by those genes. Genes that cause metastatic initiation are operating in the
primary tumor site and the distant metastatic site. This classification of the genes that are
responsible for cancer metastasis and their functions is important to provide a
multidimensional explanation of metastasis and is crucial to establish several antimetastatic strategies (Chiang & Massagué, 2008).
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Figure 2.1 Primary brain tumor epidemiology. A shows the percent distribution of all a
primary brain and CNS by histology. B shows the percent of primary brain gliomas in the
United States (2004-2006) (Agnihotri et al., 2013).
Glioblastomas or grade four gliomas are more proliferative, infiltrative, and
invasive in nature than grade one, two, and three astrocytoma (Kleihues & Sobin, 2000).
This diffusive and infiltrative nature of glioblastoma is the major reason for the surgical
incurability and disease recurrence. The malignant cells of Glioblastoma disseminate
from the primary tumor site and migrate in specific routes that depend on the structure of
the brain and the connected extra cellular matrix (Agnihotri et al., 2013). Glioblastomas
migrate commonly through dispersing in the tracks of the white matter, the basal lamina
of the brain blood vessels, or in between the glia limitans and the pia mater (Bellail,
Hunter, Brat, Tan, & Van Meir, 2004).
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2.4

Cancer Stem Cell Hypothesis

The original cell of GBM that is predicted to develop neoplastic lesions to initiate
cancer follows three possible assumptions. The first assumption is the ability of a
dedifferentiated mature glia to develop abnormal stem-cell like properties through
epigenetic lesions that is initiated by mutation. The second assumption is that restricted
neural progenitors with a limited self-renewal property can develop mutations and also
gain stem-cell like properties. The third assumption is that adult neural stem cells
(NSCs), which are normally proliferate and differentiate is capable of developing
mutations and tumor formation (Dirks, 2008; Dirks, 2001; Stiles & Rowitch, 2008).
Glioblastoma arises from cells that are able to obtain stem-cell like properties, grow
abnormally, and initiate tumor formation. This concept is the base of the cancer stem cell
hypothesis, which is shown in Figure 2.2 (Agnihotri et al., 2013). Normal cells of the
central nervous system differentiate and central nervous system tumor is initiated. Neural
stem cells are forming neural and glial progenitors, which differentiate into the principle
cell types of the central nervous system neurons, oligodendrocytes and astrocytes. Tumor
initiating cells (BTICs) are thought to come from terminally differentiated cells as shown
in Figure 2.2 and developed from the transformation of neural stem cells or neural
progenitors.
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Figure 2.2 The original cells of Glioblastoma Multiforme (Agnihotri et al., 2013).

Central nervous system (CNS) tumors are classified based on their morphological
and immunohistological characteristics which outline the predominant cell type. GBM
can be classified into two main subgroups with different genetic pathways. Primary or de
novo GBM occurs mostly in older patients with no in advance occurrence of low-grade
astrosytomas. However, secondary GBM occurs in young patients and originates from
low-grade astrocytomas as shown in figure 2.3 (Louis et al., 2007).
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Figure 2.3 GBM subtypes with different genetic pathways (Endersby & Baker, 2008)

2.5

Treatment Options for Glioblastoma Multiforme

The current standard of treatment options of Glioblastoma have not changed over
the last decades. The first line of treatment is the surgical resection of the tumor, followed
by radiotherapy. In the United States, a nitrosourea drug (carmustine) is usually
recommended ; (Walker, Laherty, Tomlinson, Chuah, & Schmidt, 2008).
Complete surgical resection of tumor mass is impossible due to the
topographically diffusive nature of the disease and the large location variability of the
tumor cells within the brain. This behavior results in the diffusion of the tumor cells
within large distances, particularly into the brain vital regions that DUHFUXFLDOIRUSDWLHQW¶s
survival. Recurrence of the tumor can occur at the surgical margin and other sites after a
total resection of Glioblastoma (Holland, 2000).
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2.6

Radiotherapy

Radiotherapy and chemotherapy are following the surgical resection of the tumor
and achieve an expected mean survival that lies between two months and one year
(Jelsma & Bucy, 1967). There is a great improvement in survival time resulting from the
combination treatment of radiotherapy and chemotherapy using temozolomide with a
median survival time of 14.6 months (Dieckmann, 2010). Modern radiotherapy aims to
increase the dose that is delivered to the tumor region, decrease the dose that is delivered
to the normal brain tissue, and avoid local necrosis (Stupp et al., 2005). The combined
treatment of radiotherapy and chemotherapy with temozolomide in Glioblastoma has
achieved a median survival of 14.6 months; however, the survival time was 12 months
only without temozolomide. The image-based conformal radiotherapy achieved two
years, which is considered crucial before and after surgical resection (Stupp, 2006; Stupp
et al., 2002).
The standard technique of radiotherapy is based on three-dimensional conformal
processes that depend on magnetic resonance imaging and x-ray computed tomography
fused data sets. There is an optimal advantage over the use of these data sets in the preoperative and the post-operative stages. The pre-operative gross tumour volume
measurement achieves a significant advantage in the postoperative structures evaluation.
Follow-up is necessary in order to increase the efficiency of the radiotherapy techniques
and to evaluate the post-treatment improvement (Dieckmann, 2010).
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2.7

Bevacizumab

%HYDFL]XPDELVDUHFRPELQDQWKXPDQL]HGPRQRFORQDO,J*DQWLERG\ZKLFK
WDUJHWVKXPDQYDVFXODUHQGRWKHOLDOJURZWKIDFWRU 9(*) DQGSUHYHQWVWKHELQGLQJRI
9(*)WRHQGRWKHOLDOFHOOVUHFHSWRUV%ORFNLQJWKHHIIHFWRI9(*)OHDGVWRWKHLQKLELWLRQ
RIWXPRUYDVFXODUJURZWK(Cohen, Shen, Keegan, & Pazdur, 2009)*OLREODVWRPDFHOOV
SURGXFHHQRUPRXVDPRXQWVRI9(*)LQVLWXDQGWKHLQKLELWLRQRIWKHVHIDFWRUVKLQGHUV
WKHJURZWKRIJOLRPD[HQRJUDIWVLQLPPXQHGHILFLHQWPLFH(Stefanik et al., 2001)
%HYDFL]XPDELVDQDQWLDQJLRJHQLFFRPSRXQGZKLFKLQKLELWWKHDELOLW\RIWKHPDOLJQDQW
JOLRPDVWRJHQHUDWHWXPRUDVVRFLDWHGEORRGYHVVHOV(Takahashi et al., 1992Maxwell et
al., 1991)
$VLQJOHDUPFOLQLFDOWULDOZDVFRQGXFWHGWRHYDOXDWHWKHELRORJLFDODFWLYLW\DQG
VDIHW\RIEHYDFL]XPDELQSDWLHQWVZLWKUHFXUUHQWKLJKJUDGHJOLRPDV'RVLQJVWUDWHJ\
FRQWDLQHGDQLQWUDYHQRXVLQIXVLRQRIPJNJEHYDFL]XPDEHYHU\ZHHNVRQDZHHN
F\FOHXQWLOWKHGLVHDVHZDVSURJUHVVHGRUPDMRUWR[LFHIIHFWVZHUHREVHUYHG3DWLHQWVZLWK
DFRQILUPHGEUDLQPDOLJQDQWJOLRPDDQGZKRZHUH\HDUVRIDJHZLWKGLVHDVH
SURJUHVVLRQDIWHUUHFHLYLQJUDGLRWKHUDS\ZHUHHQUROOHGLQWKHWULDO3DWLHQWVZLWKLGHQWLILHG
EHYDFL]XPDEULVNIDFWRUVDQGDFXWHLQWUDFUDQLDOLQWUDWXPRUDOEOHHGLQJZHUHH[FOXGHG
IURPWKHWULDO(Cohen et al., 2009)7KHHYDOXDWLRQRIWXPRUUHVSRQVHEDVHGRQWKH
PRGLILHG:RUOG+HDOWK2UJDQL]DWLRQ:+2UHVSRQVHHYDOXDWLRQFULWHULD(Macdonald,
Cascino, Schold, & Cairncross, 1990)
$QRWKHUVWXG\FRPELQHGWKHWZRZHHNLQWHUYDORILQWUDYHQRXVLQIXVLRQRI
EHYDFL]XPDE PJNJ DQGLULQRWHFDQ PJP XQWLOGLVHDVHSURJUHVVLRQPDMRU
WR[LFVLGHHIIHFWVRUDPD[LPXPRIZHHNVRIWUHDWPHQW7KHFOLQLFDOWULDOVZHUH
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GHVLJQHGWRHVWLPDWHWKHELRORJLFDODFWLYLW\DQGVDIHW\RIEHYDFL]XPDEDORQHRUFRPELQHG
ZLWKLULQRWHFDQLQSDWLHQWVZLWKUHFXUUHQWJOLREODVWRPD7KHSUHSODQQHGDFWLYLW\
HQGSRLQWVZHUHWKHPRQWK3URJUHVVLRQIUHHVXUYLYDO3)6UDWHDQGREMHFWLYHUHVSRQVH
UDWH7KHFOLQLFDOWULDOZDVFRQGXFWHGWKURXJK-XQHWR6HSWHPEHUDQG
WKHGUXJZDVDSSURYHGE\WKH86)'$RQ0D\
3HGLDWULFSKDVH,FOLQLFDOWULDORIEHYDFL]XPDEZDVFRQGXFWHGRQSHGLDWULF
SDWLHQWV ZLWKVROLGWXPRUV7KHDLPRIWKHVWXG\ZDVLGHQWLI\LQJWKHPD[LPXPWROHUDWHG
GRVH 07' DQGHVWLPDWLQJWKHGRVHOLPLWLQJWR[LFLWLHV '/7V SKDUPDFRNLQHWLFVDQG
HIILFDF\%HYDFL]XPDEZDVHIIHFWLYHLQWKHWUHDWPHQWRISHGLDWULFSDWLHQWVZLWKFRPPRQ
VLGHHIIHFWVRILQIXVLRQUHDFWLRQUDVKPXFRVLWLVDQGSURWHLQXULD%9DFKLHYHGDQ
DFFHSWDEOHWR[LFLW\SURILOHZKHQDGPLQLVWHUHGDWGRVHVRIRUPJNJHYHU\
ZHHNV1RGRVHOLPLWLQJWR[LFLWLHV '/7V ZKLFKUHTXLUHGLVFRQWLQXDWLRQRIWKHWUHDWPHQW
ZHUHREVHUYHG$VLQJOHSHGLDWULFSDWLHQWH[SHULHQFHGDORQJVWDQGLQJULVHLQERWKGLDVWROLF
DQGV\VWROLFEORRGSUHVVXUH%3DIWHUUHFHLYLQJEHYDFL]XPDEWUHDWPHQW%3HOHYDWLRQ
XVXDOO\RFFXUVLQWKHPDMRULW\RIDGXOWDQGSHGLDWULFSDWLHQWVZKRDUHWUHDWHGZLWKWKH
GUXJ7KLVVLGHHIIHFWGLGQRWPHHWWKH&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
&7&$(Y SHGLDWULFVSHFLILFFULWHULDIRUK\SHUWHQVLRQH[FHSWLQDRQHSHGLDWULFSDWLHQW
1RHIIHFWVRQRSHQHSLSK\VHVZHUHREVHUYHGGXULQJWKHOLPLWHGWLPHRIWKHFOLQLFDOWULDO
/XWHLQL]LQJKRUPRQH /+ DQGIROOLFOHVWLPXODWLQJKRUPRQH)6+OHYHOVZHUHHOHYDWHGLQ
WZRRIWKUHHSRVWPHQDUFKDOIHPDOHVZKLFKLVFRQVLVWHQWZLWKLQKLELWLRQRIWKHELRORJLFDO
IXQFWLRQRIWKHRYDU\3KDUPDFRNLQHWLFVWXGLHVVKRZHGWKDWWKHELRDYDLODELOLW\RIWKHGUXJ
ZDVSURSRUWLRQDOWRWKHGRVH(Bender et al., 2008) There were a major differences LQ
GUXJGLVSRVLWLRQLQFKLOGUHQZKLFKZHUHDOVRREVHUYHGLQDGXOWSDWLHQWV(Gordon et al.,
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2001;Gaudreault et al., 2004; Hsei et al., 2001;Lu, Gaudreault, Novotny, Lum, & Bruno,
2004)$PLQLPXPHIILFDF\ZDVREVHUYHGDIWHUFRQGXFWLQJDSKDVH,,VWXG\RIERWK
EHYDFL]XPDEDQGLULQRWHFDQRQSHGLDWULFSDWLHQWVZLWKUHFXUUHQWPDOLJQDQWJOLRPD 0* 
DQGLQWULQVLFEUDLQVWHPJOLRPD %6* (Gururangan et al., 2010)
5HJXODWRU\FRQFHUQVDERXWWKLVWULDOFRQWDLQHGWULDOGHVLJQSUREOHPVWKHODFNRI
DQLGHQWLILHGHQGSRLQWDQGWKHODFNRIDQDSSURSULDWHPHWKRGWRFRQILUPWKHUHVXOWV
(YDOXDWLQJWKHHIILFDF\RIEHYDFL]XPDELQWKHFRPELQDWLRQWKHUDS\ZLWKLULQRWHFDQLV
YHU\GLIILFXOW7KHUHLVQRVWDQGDUGUHIHUHQFHWRFRPSDUHZLWKWKHPRQWK3)6DQGWKH
RYHUDOOVXUYLYDOUDWHHQGSRLQW8VLQJDKLVWRULFDOO\FRQWUROOHGJURXSVLQWKHFRPSDULVRQ
ZLWK3)6RURYHUDOOVXUYLYDOLVXQUHDOLVWLFEHFDXVHWKH\FDQQRWEHFRQVLGHUHGDVDSURRIRI
WKHELRORJLFDODFWLYLW\RIWKHGUXJ7KHGLIIHUHQFHEHWZHHQWKHFOLQLFDOO\REVHUYHG
UHVSRQVHVDQGWKHWUXHPHDVXUHPHQWVRIWXPRUVL]HXVLQJWKHPDJQHWLFUHVRQDQFHLPDJLQJ
05,KDVHQFRXQWHUHGWKLVWULDO(Cohen et al., 2009)
7KH(XURSHDQGUXJUHJXODWRU\DJHQF\(0($ (XURSHDQ0HGLFLQHV$JHQF\ 
UHIXVHGWKHDSSURYDORIEHYDFL]XPDEIRUUHFXUUHQW*%0IRUWKHUHDVRQWKDWWKHEHQHILWV
RIEHYDFL]XPDELQWKHWUHDWPHQWRIQHZO\GLDJQRVHG*%0SDWLHQWVGLGQRWRYHUZHLJKWKH
ULVNV 5HIXVDORIDFKDQJHWRWKHPDUNHWLQJDXWKRUL]DWLRQIRU$YDVWLQ
EHYDFL]XPDE  7KHPRVWFRPPRQVLGHHIIHFWVRI%HYDFL]XPDELQFOXGHIDWLJXH
KHDGDFKHDQGK\SHUWHQVLRQ3DWLHQWVKDYHH[SHULHQFHGJUDGHRUPRUHWR[LFVLGHHIIHFWV
ZKLFKLQFOXGHGK\SHUWHQVLRQFRQYXOVLRQDUWHULDOWKURPERHPEROLVPYHQRXV
WKURPERHPEROLVPZRXQGKHDOLQJFRPSOLFDWLRQVDQGLQWUDFUDQLDOKHPRUUKDJH(Friedman
et al., 2009)7KH$YDVWLQSDFNDJHLQVHUWKDVVDIHW\LQIRUPDWLRQDERXWDUWHULDO
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WKURPERHPEROLFHYHQWVDQGLQIXVLRQUHDFWLRQVJDVWURLQWHVWLQDOSHUIRUDWLRQUHYHUVLEOH
SRVWHULRUOHXNRHQFHSKDORSDWK\V\QGURPH 53/6 QDVDOVHSWXPSHUIRUDWLRQDQGQRQ
JDVWURLQWHVWLQDOILVWXODIRUPDWLRQ )'$%ULHILQJ'RFXPHQW2QFRORJ\'UXJ$GYLVRU\
&RPPLWWHH0HHWLQJ 

2.8

Temozolomide

Temozolomide is an alkylating agent that is prescribed as a single agent for the
treatment of recurrent glioma. The drug is administered orally and exhibit antitumor
activity (Newlands, Stevens, Wedge, Wheelhouse, & Brock, 1997; W. K. A. Yung et al.,
2000).The dosing regimen consists of 150 to 200 mg for the square meter of body-surface
area to be administered once daily for 5 days of every 28-day cycle (Stupp et al., 2005).
Another dosing regimen consists of 75 mg for the square meter to be administered once
daily during seven weeks (Brock et al., 1998). Temozolomide diminishes the O6methylguanine-DNA methyltransferase (MGMT) enzyme which is responsible for the
repair of the DNA (Tolcher et al., 2003). The decrease in the O6-methylguanine-DNA
methyltransferase enzyme in tumor site is found to increase the survival of the
Glioblastoma patients who are receiving nitrosourea-based adjuvant chemotherapy
(Esteller et al., 2000; Hegi et al., 2004).
Temozolomide is a prodrug with a small size (194 Da) which is optimally
absorbed in the small intestine and penetrate the blood-brain barrier. It undergoes
spontaneous hydrolysis in the cells and converts to a strong methylating agent MTIC.
MTIC methylates the guanine as well as several base nucleobases. Nicks in the DNA are
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formed and apoptosis occur as a result of the failure of the cellular repair mechanisms to
repair the methylated base (Wesolowski, Rajdev, & Mukherji, 2010).
A randomized phase III trial showed that temozolomide had increased the median
survival and achieved a 2-year survival time after the drug was added to the standard
postoperative radiotherapy. 573 patients from 85 institutions in 15 countries were
randomly enrolled in the trial including 286 patients have received radiotherapy alone
and 287 patients have received temozolomide combined with radiotherapy. Longer
survival was observed in patients (with a methylated and un-methylated MGMT
promoter) who have received the combined therapy of temozolomide and radiotherapy
than in patients who have received radiotherapy alone (Stupp et al., 2009).
There are other three meaningful studies involved patients with malignant glioma
who have received previous treatment but encountered disease progression. One major
study had investigated the effects of Temodal in 138 patients with Glioblastoma
Multiforme. Another study compared Temodal with procarbazine in 225 GBM patients.
The final study investigated the safety and effectiveness of Temodal in the treatment of
162 patients with anaplastic astrocytoma who were in their first relapse. Effectiveness
ZDVHYDOXDWHGRQWKHEDVLVRISDWLHQWV¶VXUYLYDOWLPHDQGKRZORQJGLGLWWDNHWKHGLVHDVH
to start getting worth. The average survival time in GBM Patients was 14.6 months when
they received Temodal and radiotherapy, compared with 12.1 months with radiotherapy
alone.
The biological activity of TEMODAR in pediatric patients has not been
identified. Phase II studies on TEMODAR Capsules have been conducted in pediatric
patients (age 3-18 years) at a dose of 160-200 mg/m 2 times daily for 5 days every 28
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days. A clinical trial was conducted by the Schering Corporation in which 29 patients
with recurrent brain stem glioma and 34 patients with recurrent high grade astrocytoma
ZHUHLQYROYHG$QRWKHU3KDVHRSHQODEHOVWXG\ZDVFRQGXFWHGE\WKH&KLOGUHQ¶V
Oncology Group (COG) in which 122 patients were enrolled. The clinical trials showed
the same toxicity profile for TEMODAR in pediatric and adult patients (FDA
TEMODAR® (temozolomide) capsules, 2006).
Resistance to temozolomide is mediated by the enzyme O6-alkylguanine
transferase AGT(Stupp, Gander, Leyvraz, & Newlands, 2001). GBM Patients who have
inactivated AGT (methylated promoter) achieve more clinical benefits from TMZ than
patients with activated AGT (non-methylated promoter) (Esteller et al., 2000).
Standard carcinogenicity and reproductive function studies were not conducted
with temozolomide. Mammary carcinomas were observed in both male and female rats
after they were treated with 200 mg/m2 temozolomide on 5 days every 28 days for 3
cycles. Mammary carcinomas and fibrosarcomas of different body organs were observed
after 6 cycles of receiving temozolomide at 25, 50, and 125 mg/m2. In vitro mutagenicity
was observed in bacteria (Ames assay). Clastogenicity in mammalian cells was observed
(human peripheral blood lymphocyte assays). Multicycle toxicology studies in rats and
dogs have indicated testicular toxicity (syncytial cells/immature sperm, testicular
atrophy) at doses of 50 mg/m2 in rats and 125 mg/m2 in dogs (FDA TEMODAR®
(temozolomide) capsules, 2006).
Temozolomide received an accelerated approval by the U.S. Food and Drug
Administration in January 1999 for the treatment of anaplastic astrocytoma patients who
experienced a resistance for nitrosourea and procarbazine (W. A. Yung et al., 1999). The
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drug received full approval after the clinical benefits for temozolomide and radiotherapy
were compared with radiotherapy alone. On March 15, 2005, the FDA approved
temozolomide combined with radiotherapy for the treatment of Glioblastoma Multiforme
(Cohen, Johnson, & Pazdur, 2005). The European Committee for Medicinal Products for
+XPDQ&+03GHFLGHGWKDW7HPRGDO¶VEHQHILWVDUHJUHDWHUWKDQLWVULVNV7HPRGDO
received approval for the treatment of Glioblastoma Multiforme from The (CHMP) on 26
January 1999.

2.9

Immune Reactions in Healthy Brain

The Blood Brain Barrier BBB is a unique, selective barrier which consists of the
endothelial cells and perivascular elements such as closely associated astrocytic end-feet,
perivascular neurons and pericytes as shown in figure 2.4 (a). Several membrane
transporters are present in the brain endothelial cells. They are responsible for the
regulation of the penetration of essential molecules from the blood circulation into the
brain. Membrane transporters are also responsible for the effluxing of potentially harmful
substances and waste products out of the brain cells. P-glycoprotein (P-gp) and the
multidrug resistance-associated protein family are the most important efflux transport
systems responsible for drug delivery to the CNS. The presence of complex tight
junctions (TJ) and adherens junctions (AJ) makes the cerebral endothelial cells very
unique. TJs prevent the penetration of polar molecules into the brain, however AJs
stabilize cell±cell interactions in the junctional zone. In addition, there are intracellular
DQGH[WUDFHOOXODUHQ]\PHVVXFKDVPRQRDPLQHR[LGDVH 0$2 Ȗ-glutamyl transpeptidase
Ȗ-GT), alkaline phosphatase, peptidases, nucleotidases and several cytochrome P450
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enzymes which provide the BBB with the metabolic activity as shown in figure 2.4 (b)
(Cecchelli et al., 2007).

Figure 2.4 The cells of the BBB (a) and the existing membrane transporters (b)
(Cecchelli et al., 2007).
It was thought that immune reactions do not occur in the brain due to the specific
nature of the blood brain barrier. The brain has specific characteristics such as the
absence of conventional lymphatic vessels and decreased number of circulating T cells. It
is recently known that the central nervous system communicates with the immune system
by the means of two-way communication pathways. Recent models such as infectious or
experimental autoimmune encephalomyelitis animal models provide information about
the specific operations of the immune system in the brain (Vauleon, Avril, Collet,
Mosser, & Quillien, 2010).
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A healthy brain contains several different immune cell populations. Microglial
cells resemble 5% to 20% of cells in the central nervous system starting from the
embryonic development. Microglial cells arise from hematopoietic cells and are
considered as the first line of defense in the brain. Macrophages and dendritic cells (DC)
are present in perivascular zones, the choroid plexuses, and the meninges. Macrophages
and dendritic cells arise from the monocytes which are circulating in the blood stream
(Vauleon et al., 2010).
Microglial cells travel to the inflammatory zones. undergo activation, obtain
phagocytic properties, and produce different types of cytokines and chemokines which
synthesise other types of immune cells (Tambuyzer, Ponsaerts, & Nouwen, 2009). The T
cells are being activated in the cervical nodes, resulting in increasing the levels of Į4/ȕ7
integrins. Animal models showed that antigen presenting cells (APC) travel from the
brain parenchyma through the external capsule to enter the cervical nodes which is the
same drainage system pathway in humans and rodents (Karman, Ling, Sandor, & Fabry,
2004).
The blood brain barrier exhibits a selective penetration of immune cells from the
blood circulation into the brain parenchyma due to the complex cellular structure of the
brain capillaries such as; endothelial cells with tight junctions, pericytic cells, and
astrocytic cells. The penetration of the activated T cells across the blood brain barrier is
controlled by rolling, activation, adhesion, and transmigration.
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The process is also controlled by several molecular interactions involving adhesion
PROHFXOHVVXFKDVĮȕLQWHJULQVDQGFKHPRNLQHVVXFKDV&XCR3 (Mrass & Weninger,
2006; Wilson, Weninger, & Hunter, 2010).
2.10 Immune Reactions in GBM patients
It is obvious that the rules that regulate the penetration of the effector T cells
across the tumour tissues and the normal state rule are different (Vauleon et al., 2010).
The blood brain barrier in GBM patients has abnormal asymmetric capillary structure.
The tight junctions between endothelial cells are inactivated and the blood brain barrier
associated pericytes are decreased in number (Mrass & Weninger, 2006; Davies, 2002;
Rascher et al., 2002). The travelling of lymphocytes was tracked with injections of CD4+
lymphocytes in a model of autoimmune encephalitis to target myelin proteins.
CD4+ lymphocytes entered the subarachnoid spaces and travelled through the
internal wall first then through the external walls of the vessels. When CD4+ lymphocytes
identify any Antigen Presenting Cells APC such as macrophages or dendritic cells in the
myelin antigens, they become reactivated, produce numerous cytokines, and enter the
brain parenchyma (Bartholomäus et al., 2009). CD8+ lymphocytes are locally expanded
depending on the brain environment. Glioma mouse model showed that CD8+
lymphocytes first enter the brain, then undergo proliferation and differentiation
depending on IFNȖand granzyme B expression (Vauleon et al., 2010). CD8+ T cells have
the ability to retain into the brain due to the presence of ĮEȕ7 integrins (Masson et al.,
2007). This increased level of ĮEȕ7 integrins is thought to be resulting from the presence
of TGFȕ(Vauleon et al., 2010). The infection models showed that CD8+ T cells also have
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the ability to expand in the brain depending on the overexpression of the dendritic cells
(Lauterbach, Zuniga, Truong, Oldstone, & McGavern, 2006).

2.11 Immunotherapy for Glioblastoma Multiforme
The occurrence of effective anticancer immune response is initiated and
maintained by a series of stepwise events called the cancer-immunity cycle as shown in
figure 2.5. In step 1, neoantigens are formed and released by oncogenesis and captured
and processed by dendritic cells (DCs). In step 2, DCs present the captured antigens on
MHCI and MHCII molecules to T cells. T cell responses against the cancer-specific
antigens are primed and activated in step 3. In steps 4, 5, 6, and 7, the activated effector T
cells traffic to, infiltrate the tumor bed, specifically recognize, bind to, and kill their target
cancer cell. The cancer-immunity cycle is iterative because the death of the cancer cell
releases additional tumor-associated antigens which strengthen the previously explained
immune response (D. S. Chen & Mellman, 2013). The Cancer-Immunity Cycle is limited
in GBM patients because the tumor antigens may not be detected and DCs and T cells
may not recognize antigens as foreign. Moreover, T cells may not properly home to
tumors, or may be inhibited from infiltrating the tumor. The suppression of those effector
cells by tumor microenvironment is another important factor that also may limit the
Cancer-Immunity Cycle ( Motz & Coukos, 2013).

The presence of checkpoints and inhibitors in each step of the cancer-immunity
cycle may negatively affect the production of the antitumor immune response.
Checkpoints of cancer-immunity cycle are common rate-limiting steps and exhibit
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immunostat function that takes place in the tumor microenvironment and cause
immunosuppression (Jarrod Predina et al., n.d. ; Wang et al., n.d. ). Each step of the
Cancer-Immunity Cycle has stimulatory; which initiate and maintain immunity and
inhibitory factors; which inhibit immunity and also prevent autoimmunity. For example,
CTLA4 is an immune checkpoint protein; which works on step 3 to prevent the
development and proliferation of t cells and hinder the desired active immune response.
There are also immune rheostat (immunostat) factors, such as PD-L1; which acts on step
7 and modulate active immune responses in the tumor bed. Stimulatory and inhibitory
factors of Cancer-,PPXQLW\&\FOHDUHVKRZQLQWDEOH7KHVHIDFWRUVLQFOXGH³IL,
interleukin; TNF, tumor necrosis factor; IFN, interferon; CDN, cyclic dinucleotide; ATP,
adenosine triphosphate; HMGB1, high-mobility group protein B1; TLR, Toll-like
receptor; HVEM, herpes virus entry mediator; GITR, glucocorticoid-induced TNFR
family-related gene; CTLA4, cytotoxic T-lymphocyte antigen-4; PD-L1, programmed
death-ligand 1; CXCL/CCL, chemokine motif ligands; LFA1, lymphocyte functionassociated antigen-1; ICAM1, intracellular adhesionmolecule1; VEGF, vascular
endothelial growth factor ;IDO,indoleamine2,3-dioxygenase; TGF, transforming growth
factor; BTLA,B-and T-lymphocyte attenuator; VISTA, V-domain Ig suppressor of T cell
activation; LAG-3, lymphocyte-activation gene 3 protein; MIC, MHC class I
polypeptide-related sequence protein; TIM-3, T cell immunoglobulin domain and mucin
domain-3´. These factors arise from the intratumoral T regulatory cells, macrophages,
and myeloid-derived suppressor cells. There are also specific immunogenic signals such
as proinflammatory cytokines and factors released by dying tumor cells that are crucial
for the production of an anticancer T cell response (D. S. Chen & Mellman, 2013).
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Figure 2.5 The cancer-immunity cycle (D. S. Chen & Mellman, 2013).
Table 2.1 Positive and negative regulators of the cancer-immunity cycle (D. S. Chen &
Mellman, 2013).
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The use of immunotherapy for the treatment of brain tumors consists of two
options. The first option is the use of active immunotherapy that aims to increase the
native immune response in Glioblastoma patients. The second option is the use of passive
immunotherapy to target the tumor cells. Passive immunotherapy consists of in vitro
activated immune cells or specific molecules such as antibodies which can be injected
directly (Vauleon et al., 2010).

2.12 Adoptive Immunotherapy
The in vitro activated immune cells are either being directly injected into the
tumor tissues or intravenously in GBM patients (Vauleon et al., 2010). Lymphocyteactivated killer cells are used for the treatment of Glioblastoma patients (Jacobs, Wilson,
Kornblith, & Grimm, 1986; Robert Owen Dillman et al., 2009). There are several
clinical trials that were conducted on a number of High Grade Glioma patients and based
on the use of lymphocyte activated killer cells LAK (Vauleon et al., 2010). The toxic
effects of LAK include neurological toxicity and brain edema (Barba, Saris, Holder,
Rosenberg, & Oldfield, 1989). Radiological response criteria were used to evaluate the
improvement after the treatment was received by patients. One hundred and eighteen GG
patients were enrolled in some LAK cells clinical trials; five patients were reported with a
complete response, 13 patients with a partial response, and six patients with stable
disease (Vauleon et al., 2010). Vaccinated Glioblastoma patients achieved a longer
median survival than the median survival of the control groups (Hayes et al., 1995; Hayes
et al., 2001; Robert O. Dillman et al., 2004). In one clinical trial, the median overall
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survival of a newly diagnosed GBM patients reached 20.5 months and one year for 75%
of the patients (Robert Owen Dillman et al., 2009).
Cytotoxic T lymphocytes (CTL) are also used for the treatment of GBM
patients (Vauleon et al., 2010). Several clinical trials were conducted to evaluate the
efficacy of cytotoxic T lymphocytes (CTL) on High Grade Glioma patients. Cytotoxic T
Lymphocytes were delivered to the cerebrum by direct injection into the tumor site
(Vauleon et al., 2010). In some clinical trials, cytotoxic T lymphocytes were generated
from lymph nodes or peripheral blood mononuclear cells and were combined with
vaccination strategy in 65 patients. The combination strategy of both immune cells were
delivered to the tumor site either by intravenous injection or by intracarotid infusion. The
reported side effects include a hypersensitivity reaction at the injection site. The degree of
tolerance was acceptable and no disease progression was reported (Vauleon et al., 2010).
Ninety-five patients were treated with this combination therapy and were assessed as
follows: 18 patients with a stable disease state, 28 patients with partial response, and
three patients with complete response. One clinical trial has reported a survival time up to
eight months in seven of 15 patients and up to 40 months in one patient (Holladay, HeitzTurner, Bayer, & Wood, 1996).

2.13 Active Immunotherapy
There are different cells such as intact tumor cells, tumor protein lysates, tumorderived mRNA, and natural and synthetic peptides which can be used as antigen sources
for the active immunotherapy. Antigens can be used alone or with dendritic cells and
combined with other adjuvants to increase the immune response (Vauleon et al., 2010).
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Autologous tumor cells (ATC) was used as vaccines in several clinical trial studies
for the treatment of High Grade Glioma patients. The cells are injected either
subcutaneously or intradermally. Several clinical studies reported that the vaccination
procedure should be repeated for three cycles with a total of one to 13 injections. Side
effects include fever, erythema, and abnormal liver tests (Vauleon et al., 2010). Fiftythree high Grade Glioma patients were enrolled in several clinical studies based on the
treatment with autologous tumor cells and the patients were assessed as follows: four
patients with complete response, six patients with partial response, two patients with
minor response, and six patients with stable disease.
Vaccination based on dendritic cells is very useful for the treatment of GBM
especially for patients with small tumors. The antigens were derived from tumor lysates,
peptides or mRNA that are obtained from autologous tumor cells ATC or the whole ATC
in several clinical studies. Tolerance was manageable with the rare incidence of grade
four neurotoxicity (Yamanaka et al., 2005). Side effects include; headache, seizure, and
flu-like syndrome. This treatment strategy was found to initiate a peripheral immune
response in large percent of patients who were enrolled in the clinical studies.
Further investigation on a number of patients who received vaccination showed
that CD8 lymphocytes were specifically expressed. The analysis of the radiological
response of c Thirty-four Glioblastoma patients who have responded to the vaccination
WUHDWPHQWVKRZHGDPDMRULQFUHDVHLQ,)1ȖSURGXFWLRQKRZHYHUQRRYHUSURGXFWLRQZDs
detected in nonresponsive patients. The responded patients also experienced an enhanced
response to the chemotherapy which was administered in a second phase (Wheeler et al.,
2008). When dendritic cells were exposed to the proper antigens, they enabled the
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adaptive immune system to produce immune response and eradicate tumor cells (Wang et
al., 2014).
Early vaccinated Glioblastoma patients with high intratumoral infiltration by T
lymphocytes were found to experience a small level of intratumoU7*)ȕDQG longer
survival. Patients with major tumors who were vaccinated late showed no infiltration in T
lymphocytes, experienced high levels of intratumoU7*)ȕDQGDFKLHYHGOHVVWKDQ
months of overall survival (Liau et al., 2005). Glioblastoma patients who have received
mature dendritic cells achieved longer survival than patients who have received immature
dendritic cells. The co- administration of both peripheral and intracranial dendritic cells
showed a more optimum response than peripheral injection only (Yamanaka et al., 2005).
A combined therapy of dendritic cells (DC) that was obtained from monocytes and
temozolomide in a primary treatment course of therapy was tested on 14 Glioblastoma
patients. Two patients were reported with positive antitumor immune responses in the
peripheral blood (Hunn et al., 2015).

2.14 DC Development, Diversification, Maturation, and Function
Dendritic cells (DCs) are antigen presenting cells, which have the ability to
stimulate the native T cells and induce primary immune responses and peripheral
immunological tolerance. Immature DCs (im DCs) originates from hematopoietic stem
cells within the bone marrow. The process of development and diversification of DCs is
antigen-independent. CD34+ hematopoietic stem cells differentiate into common myeloid
progenitor cells (CMP) and common lymphoid progenitor cells (CLP). The CMPs
differentiate into CD34+ CLA+ and CD34+ CLA- late progenitor cells. While CD34+
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CLA+ cells differentiate into CD11c+ CD1a+ Langerhans cell precursors, CD34+CLAcells differentiate into CD11c+ CD1a- interstitial DC precursors in blood. The blood
CD11c+ CD1a+ Langerhans cell precursors migrate into the skin epidermis and become
Langerhans cells and the CD11c+CD1a- migrate into the skin dermis and other tissues to
become interstitial DCs. In case of the absence of antigen/pathogen stimulation, both
Langerhans cells and interstitial DCs play a critical role in immune tolerance in the
lymph nodes. After being stimulated by microbes, Langerhans cells and interstitial DCs
become mature and rapidly induce primary immune responses. CMP and CLP also
differentiate into Phenotype myeloid pre-DC1s and lymphoid pre-DC2s in bone marrow.
After bacterial infection, pre-DC1s recognize and destroy bacteria, differentiate into DCs,
and initiate adaptive antibacterial immune responses. After viral infection, pre-DC2s
triggers the production of type-1 IFN, differentiate into DCs, and initiate adaptive
antiviral immune responses as shown in figure 2.6 (Yong-Jun Liu, n.d.).

Figure 2.6 DC Development, Diversification, Maturation, and Function (Yong-Jun Liu,
n.d.).
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Tyrosinase-5HODWHG3URW´QG , AIM-2 (Zhang et al., 2007; ³$,0-´QG , gp100,
MAGE1, and ,QWHUOHXNLQUHFHSWRUĮ-chain IL13Ra2 (Zhang et al., 2007; Liu et al.,
2004; Okano, Storkus, Chambers, Pollack, & Okada, 2002).

Furthermore, CD133 is a stem cell marker which is overexpressed on GBM cells
and was found to result in radio- resistance, chemo-resistance, and tumor aggressiveness.
CD133 was found to be increased by 4.6-fold in recurrent GBM cells compared with the
percentage in primary GBM cells (Pallini et al., 2011). Several studies have shown that
cytomegalovirus phosphoprotein 65pp65 HCMV is also expressed in more than 90% of
GBM specimens in contrast with normal brain (Dziurzynski et al., 2012; Cobbs et al.,
2002); which suggests that HCMV viral proteins may be used as tumor-specific target
(Mitchell et al., 2015).

2.16 End Points and Evidences of Therapeutic Activity

One of the primary end points is the Overall survival (OS) which was defined as
³WKH time from the day of surgical tumor resection until the date of death due to any
cause´. Another end point is the Progression-free survival (PFS) which was defined as
³the time from the day of surgical tumor resection until the first documented progression
in MRI or death due to any cause whichever is earlier´ (Akasaki et al., 2016).
Objective tumor response is considered as a targeted end point in some clinical
trials. It is measured by investigating the presence of a complete response, partial
response, progressive disease, or stable disease. Complete response (CR) is defined as the
complete disappearance of all lesions for 4 weeks. Partial response (PR) is defined as the
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50 % reduction in tumor size for 4 weeks. Progressive disease (PD) is defined as 25 %
increase in tumor size or appearance of new lesions. Stable disease (SD) is neither PD or
PR as shown in 2D categorization criteria shown in table 2.3 (Miller, Hoogstraten,
Staquet, & Winkler, 1981).
Table 2.3 1D and 2D response categorization criteria (Shah et al., 2006).
Method
1D
2D

% CR
100
100

Response Category
% PR
% SD
>30
30 to 20
>50
25 to 25

% PD
>20
>25

2.17 Nanotechnology in Immunotherapy for GBM
There is a great need for an optimized therapy for the treatment of GBM.
Although, immunotherapy is considered a potential treatment for glioblastoma, it
still faced by major limitations such as target identification, delivery system, and
local suppression of the immune system (Patel, Kim, Ruzevick, Li, & Lim, 2014).
The blood brain barrier blood brain barrier BBB prevents large particles from
penetrating into the brain to be delivered to the tumor site. Increasing the dose of
the therapeutics will cause toxic side effects due to the decreased local
bioavailability and the accumulation of the medicines into the vital organs
through the reticuloendothelial system (Ung & Yang, 2015). Nanotechnology can
be used to increase the efficacy of new therapeutics and decrease the toxic side
effects (Nduom, Bouras, Kaluzova, & Hadjipanayis, 2012). The particle size,
morphology, composition, and surface modifications of the nanoparticles can be
controlled and modulated according to the intended use and the selected target as
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shown in Figure 2.3. Nanoparticles are synthesized from carbon, lipids, or
polymeric units can carry and deliver different active ingredients locally to the
tumor cells and avoid normal cells. Nanoparticles can enhance the efficacy of the
immunotherapy that is used as a potential treatment for glioblastoma Multiforme.
Nanoparticles can selectively target interleukin-13 receptors which are
overexpressed in the tumor cells. This mechanism of selective targeting has a
great advantage of minimizing toxic side effects especially in the healthy tissues
(Ung & Yang, 2015).
Dendritic nanoparticles or dendrimers consist of large number of
oligomeric branches and several surface groups. They can be modified due to the
large number of branching units using a wide range of functional groups to
improve the immunotherapy for Glioblastoma Multiforme. Dendrimers were
grafted to both doxorubicin and siRNA (Ofek, Fischer, Calderón, Haag, & SatchiFainaro, 2010). Dendritic nanoparticles achieved high degree of selectivity and no
cytotoxicity effects were reported. The use of siRNA loaded in a nanoparticle is
considered a potential treatment especially in the gene therapy approach for the
treatment of GBM (Ofek, Fischer, Calderón, Haag, & Satchi-Fainaro, 2010).
Nanoparticles is a potential solution which can be used to overcome the major
limitations of the immunotherapy for GBM. They exhibit a great ability to attach
efficiently with the targeted sites, deliver different treatments in a concentrated
and controllable manner to the tumor tissues, and reducing the toxic side effects
(Ung & Yang, 2015).
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Figure 2.7 Different shapes and compositions of nanoparticles that are used in drug
delivery (Faraji & Wipf, 2009).

2.18 Summary
This chapter has provided an overview to the review of relevant literature. It has
provided Glioblastoma Multiforme (GBM), epidemiology, metastases, cancer stem cell
K\SRWKHVLVWUHDWPHQWRSWLRQV³5DGLRWKHUDS\%HYDFL]XPDE, and 7HPR]RORPLGH´
immune reactions in healthy brain and in Glioblastoma patients, immunotherapy for the
treatment of GBM, adoptive immunotherapy, active immunotherapy, DC development,
diversification, maturation, and function and nanotechnology in immunotherapy for the
treatment of GBM. It also has introduced an overview of the tumor associated antigens
TAAs, and end points and evidences of therapeutic activity.
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CHAPTER 3. METHODOLOGY

This chapter provides the methodology of investigating the DC- based vaccination
immunotherapy option for GBM that includes data collection procedures, data sources,
and data analysis techniques.

3.1

Data Collection

This study is conducted to explore the clinical outcomes of DC vaccines; which are
currently under investigation for the treatment of GBM. Clinical trials showed that
treating GBM patients with surgery, TMZ, and Dendritic Cell DC vaccines was safe and
achieved meaningful clinical outcomes. The sources of antigen that have been used in DC
immunotherapy include exogenous MHC-restricted peptides, acid-eluted tumor peptides,
tumor cell lysate, and whole glioma cells. The study is exploring the efficiency of the
treatment combination of immunotherapy, chemotherapy, following surgical resection of
the tumor mass based on OS and PFS values. Data about the inclusion criteria of GBM in
published clinical trials, pre and post vaccination treatment strategies, antigen sources,
and immune responses that are related to the relatively most preferable clinical outcomes
(OS and PFS) has been considered.
3.2
Data will be collected from:

Data Sources
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9 The official site of the Food and Drug Administration Agency.
9 The official site of the European Medicines Agency.
9 Clinical trials websites.
9 The published literature of the clinical trials; which were conducted on GBM
patients.
3.3

Data Analysis

An independent samples t-test has been used to compare the means of OS and
PFS values of independent sample groups of GBM patients. Data has been collected from
published results of the clinical trials conducted on GBM patients who were involved in
different treatment strategies. Moreover, ANOVA test has been performed to compare
the means of OS and PFS values of two or more independent sample groups of GBM
patients and to show graphical displays.
The first independent samples t-test has been performed to determine the presence
of a statistically significant difference of OS and PFS values between 2 groups of
patients. The first group received DC based vaccination pulsed with specific antigens
(SA) with concomitant or post vaccination TMZ. The sources of SA antigens include the
synthetic class I peptides AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2 or
the synthetic peptides TRP-2, gp100, her-2/neu, and survivin. The second group received
DC based vaccination loaded with tumor material antigens (TM) and concomitant or post
vaccination TMZ. The sources of TM antigens include autologous tumor or glioma cells.
The second independent samples t-test has been performed to determine the
presence of a statistically significant difference of OS and PFS values between two
groups of GBM patients. The first group have received DC vaccine + concomitant or post

39
vaccination TMZ and did not receive pre-vaccination TMZ (Nil). The second group have
received pre-vaccination TMZ + DC vaccine + concomitant or post-vaccination TMZ
(TMZ).
The third independent samples t-test has been performed to determine the
presence of a statistically significant difference of OS values between two groups of
GBM patients. The first group received pre-vaccination TMZ + RT + DC vaccine +
concomitant or post-vaccination TMZ (TMZ+RT). The second group of GBM patients
DC vaccine + concomitant or post vaccination TMZ and did not receive pre-vaccination
therapy (Nil).
The fourth independent samples t-test has been performed to determine the
presence of a statistically significant difference of PFS values between two groups of
GBM patients. The first group received pre-vaccination TMZ + RT + DC vaccine +
concomitant or post-vaccination TMZ (TMZ+RT). The second group of GBM patients
received DC vaccine + concomitant or post vaccination TMZ and did not receive prevaccination therapy (Nil).
ANOVA test has been performed to determine the presence of a statistically
significant difference between the means of OS and PFS values of two groups of GBM
patients. The first group includes patients who received DC based vaccination +
concomitant or post-vaccination TMZ with or without RT. The second group includes
patients who received TMZ+RT with no DC vaccine.
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3.4

Summary

This chapter has presented the different elements of the research methodology. It
shows data collection procedures, data sources, and data analysis techniques of this
research.
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CHAPTER 4. DATA COLLECTION, DATA ANALYSIS, AND FINDINGS

This chapter presents the data which has been collected to investigate the clinical
outcomes of using different DC- based vaccination strategies, immune responses that are
accompanied by the most preferable clinical outcomes, data analysis, and findings.

4.1

Data Collection

3DWLHQWV¶LQIRUPDWLRQWKHLQFOXVLRQFULWHULDLQSXEOLVKHGFOLQLFDOWULDOVSUHDQG
post vaccination treatment strategies, antigen sources, immune responses that are related
to the relatively most preferable clinical outcomes (OS and PFS) have been collected.

4.1.1

Clinical Outcomes

Different clinical outcomes were associated with DC- based vaccination therapy
loaded with different antigens which were obtained from different antigen sources. The
sources of antigen that have been used in DC immunotherapy include synthetic class I
peptides AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2, synthetic peptides
TRP-2, gp100, her-2/neu, and surviving, and autologous tumor or glioma cells. Clinical
trials showed that treating GBM patients with surgery, TMZ, and Dendritic Cell DC
vaccines was safe and achieved meaningful clinical outcomes. OS and PFS are the most
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widely used end point in clinical trials. Different values of OS and PFS reached
by GBM patients involved in different treatment strategies have been investigated.

4.1.1.1 Conventional Treatment with TMZ+RT

Data were obtained from the (EORTC 26981/22981) phase 3 clinical trial; which was
conducted to prove the efficacy and safety of TMZ combined with RT in comparison to RT
alone. This trial included 573 patients, 287 were treated with RT+TMZ and 286 patients were
treated with RT alone. Kaplan Meier curves show the survival distributions achieved with RT +
TMZ. The median overall survival was 14.6 months and the median PFS was 6.9 months for
patients who were treated with TMZ+RT. 61% of GBM patients reached 1-year OS and 26%
achieved 2 years OS after being treated with RT + TMZ. The efficacy results are shown in figure
4.1 and figure 4.2 (EMA, n.d.).

Figure 4.1 Kaplan-Meier Curves for Overall Survival with (TMZ+RT) (EMA, n.d.).
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Figure 4.2 Kaplan-Meier Estimates for Progression-Free Survival with TMZ+RT (EMA ,
n.d.).

4.1.1.2 DC Vaccine improves Responses to Chemotherapy

The treatment of GBM patients with DC vaccine in combination with standard
adjuvant therapy has showed safety and efficacy. The values of overall survival of 13
patients with malignant astrocytoma who were treated with DC vaccination and
conventional therapy are shown in table 4.1. The age of recruited patients varied between
1±75, the performance status ECOG (Eastern Cooperative Oncology Group) was 0, 1 or 2
(Walker et al., 2008). The ECOG performance status of 0, 1, and 2 is equivalent to t 70%
of Karnofsky performance status (Oken et al. 1982). Three out of eight GBM patients had
progressive disease and five patients showed an objective radiological response to
treatment. One patient showed a complete response, which persisted for three months.
There were no adverse events attributed to the use of DC vaccines. This study

44
demonstrated that the improvements of patient responses to adjuvant chemotherapy were
related to the use of DC vaccines (Walker et al., 2008).

4.1.1.3 Clinical Outcomes of the Treatment Strategy of DC Vaccine loaded with Tumor
Material (TM) and Chemotherapy

A phase 1 clinical study showed that treating GBM patients with surgery, TMZ,
autologous tumor material loaded DC vaccines, and further TMZ was safe and achieved a
limited efficacy as shown in table 4.2. Information regarding enrolled patients and
previous treatment strategies are shown in Table 4.3. The 6 months PFS for all treated
patients (n =9) was 22 % which is similar in the combined treatment and the treatment
with TMZ alone. The median OS from the original diagnosis of GBM for the treated
patients was 23 months. No grade IV toxicities or DC related toxicity were detected. The
reported adverse events of the combined therapy were only attributed to the anticipated
toxicity of TMZ (Hunn et al., 2014).

A clinical trial was designed to evaluate the safety and clinical responses of two
groups of GBM patients treated with a combined therapy of TMZ and fusions of DCs and
glioma cells (FC). Group-R included patients (n = 10) with recurrent GBM patients after
failing TMZ-chemotherapy and Group-N included newly diagnosed GBM patients (n =
22). The selection criteria included D.DUQRIVN\SHUIRUPDQFHVWDWXV .36 RIDQG
the age average was 54.6 years.The medians, first quartiles, third quartiles, and 95 %
CIlow of medians were evaluated as shown in figure 4.3 (Akasaki et al., 2016).
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Table 4.1The results of a phase I dendritic cell vaccine and standard adjuvant therapy
trial for malignant astrocytoma (Walker et al., 2008).

Table 4.2 The clinical outcomes of using TMZ + monocyte-derived dendritic cells (DC)
pulsed with autologous tumor cells (Hunn et al., 2014).
Patient

Vaccination
Received
(Prime + Boost)

Cycles of TMZ
Received

Time to Progression
(Months)

Overall Survival
From Inclusion
(Months)

A01
A02
A05
A06
A08
A09
A12
A13
A14

3+6
3+3
3+3
3+5
3+6
3+2
3+3
3+2
3+1

6
4
4
4
6
2
3
2
2

31.5
5
2
6
12.3
3
5.3
2
3.5

40
7
7
10
14
7.8
6
7.8
10.5
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Table 4.3 Patients data and information about previous treatment (Hunn et al., 2014).

Figure 4.3 The Kaplan±Meier curves of a PFS and b OS of recurrent GBM patients, c
PFS and d OS of newly diagnosed GBM patients after being treated with TMZ and FC
(Akasaki et al., 2016)
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The phase 1 clinical trial was conducted on 34 patients with malignant glioma and
treated with autologous tumor lysate-pulsed DC (ATL-DC) (28 patients). The study
demonstrated the absence of dose-limiting toxicity on GBM patients. Clinical outcomes
which were expressed as PFS and OS values are shown in table 4.5 (Prins et al., 2013).
4.1.1.4 Clinical Outcomes of the Treatment Strategy of DC Vaccine loaded with Tumor
Specific Antigens (SA) and Chemotherapy
ICT-107 is an autologous vaccine consisting of patient DC pulsed with six
synthetic class I peptides (AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2).
These antigens are known tumor specific antigens and some of them are overexpressed
on Cancer Stem Cells CSCs. A single-arm phase I study was conducted on 21 GBM
patients whose tumors expressed at least three of these antigens. Patients with newly
diagnosed and recurrent GBM who had their tumor resected and received a standard
treatment of TMZ and RT were recruited. Patients were treated with ICT-107 vaccine to
investigate its immunogenicity, safety and efficacy. After receiving DC based
vaccination, patients with newly diagnosed GBM received TMZ and patients with
recurrent GBM received TMZ with or without bevacizumab. Clinical outcomes were
evaluated as PFS and OS in months as shown in table 4.4 (Phuphanich et al., 2012).
Median PFS in newly diagnosed patients was 16.9 months, and median OS was
38.4 months. 55.6 % of the treated patients reached three-year overall survival. The
Kaplan±Meier probability curves of PFS and OS are shown in Figure 4.4 (Phuphanich et
al., 2012).
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Table 4.4 Clinical outcomes of ICT-107 vaccine on GBM patients (Phuphanich et al.,
2012).

Figure 4.4 The Kaplan±Meier probability curves of (a) PFS and (b) OS of GBM patients
(n=16) (Phuphanich et al., 2012).
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The phase 2 clinical trial has been conducted to determine the safety, efficacy,
and the ability to stimulate the immune response of 124 GBM patients of ICT-107 after
surgery and chemotherapy. A phase 3 clinical trial is also under investigation
(Clinicaltrials.gov, 2016).
The phase 1 clinical trial was conducted on 34 patients with malignant glioma and
treated with glioma-associated antigen peptide-pulsed DC vaccination (GAA-DC) (six
patients). The study demonstrated the absence of dose-limiting toxicity on GBM patients.
The trial used the synthetic peptide antigens TRP-2, gp100, her-2/neu, and survivin
which are known to be expressed by gliomas (Andersen et al., 2013; Zhang et al., 2008).
Clinical outcomes which were expressed as PFS and OS values are shown in table 4.5
(Prins et al., 2013).

4.1.2 Immune Responses and Prognostic Biomarkers
Assays that measure the immune responses are crucial for the detection of antitumor responses that were developed after DC vaccine. Different tumor specimen
analysis and assays such as the immunohistochemical analysis and CTL assays have been
performed in clinical trials to determine immune responses that are strongly related to
improvements in OS and PFS to identify new prognostic biomarkers.
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Table 4.5 OS, PFS, and clinical characteristics of GBM patients who were either treated
with ATL-DC (n = 28) or GAA-DC (n=6) (Prins et al., 2013).

4.1.2.1 Tumor-Specific Cytotoxic T Lymphocyte CTL Responses

CTL assays were used to determine systemic tumor-specific cytotoxicity in GBM
patients who received dendritic cell vaccine pulsed with acid-eluted tumor peptides as
shown in figure 4.5. Patients who developed post-vaccination peripheral tumor-specific
CTL activity have reached longer survival and did not experience progressive disease in
contrast with patients who did not develop post-vaccination CTL.
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Figure 4.5 Peripheral CTL responses to autologous DC vaccine pulsed with acid-eluted
tumor peptides. Negative CTL in patient (A) and positive CTL in patient (B) (Liau et al.,
2005).
The up-regulation of several glioma-associated antigens such as WT-1 (M. Y.
Chen et al., 2010), gp-100 (Xie, Nguyen, Hupe, & Wei, 2009), and MAGE-A3 (Monte et
al., 2006) makes the tumor cells resistant to chemotherapy. These antigens are known as
chemo resistance associated peptides (CAPs). The assessment of CTL responses against
these TAAs was performed to investigate the correlating with OS as shown in figure 4.6.
Antigen-specific CTL responses against WT-1 (a), gp-100 (b), and MAGE-A3 (c) were
detected in four patients who reached the longest OS after vaccination with FCs.
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The OS was 17.8 months in patient 1, 21.2 months in patient 2 , > 36 months in
patient 3, and reached > 48 months in patient 4 (Akasaki et al., 2016) .

Figure 4.6 Expression of WT-1, gp-100, and MAGE-A3 in 4 GBM patients (Akasaki et
al., 2016).

4.1.2.2 CD3+, Tumor-Infiltrating Lymphocytes (TIL), and Transforming Growth
Factor-ȕ7*)ȕ

Immunohistochemical analysis of tumor specimens from the pre-vaccination and
post-vaccination surgery has been performed. Cytotoxic T cells CD8+ and memory T
cells (CD45RO) infiltrates were found to be elevated in all post-vaccination specimens
compared with the pre-vaccination specimen. The elevation of cytotoxic T cells CD8+
after vaccination is shown in figure 4.7 (Walker et al., 2008).
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Figure 4.7 Cytotoxic T cells CD8+ (dark cells) in malignant astrocytoma tissue before
DC vaccination (a), and after DC vaccination (b) (Walker et al., 2008) .

Patients with robust infiltration of CD3+ and tumor-infiltrating lymphocytes (TIL)
such as CD8+, CD45RO+ memory T cells, and CD4+ helper T cells reached >30 months
OS as shown in figure 4.9 (A and B). Those patients also had lower expression of
transforming growth factor-ȕ 7*)ȕLQWKHLU*%M cells samples as shown in figure 4.8.
The accumulation of TGF-ȕZLWKLQWKHWXPRUPLFURHQYLURQPHQWPD\UHVXOWLQWKH
absence TIL infiltration and a clinically significant antitumor immune response in GBM
patients. Patients with no significant difference in the infiltration of TIL as shown in
figure 4.9 (C) have experienced tumor progression and died within 1 year. Figure 4.9 (D)
also shows a control group of GBM patients who did not receive DC vaccination (Liau et
al., 2005). A recent study also showed a significant correlation between high TIL content
and increased OS and PFS (Sedighim et al., 2016).
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Figure 4.8 TGF-E2 expressions in GBM specimens. Analysis of TGF-E2 mRNA (A),
high TGF-E2 (B), low TGF-E2 protein expression (C) in GBM tissue (Liau et al., 2005).

Figure 4.9 Infiltration of TIL into GBM cells after receiving DC vaccine pulsed with
acid-eluted tumor peptides (Liau et al., 2005).
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4.1.2.3 Immune Responses to Specific TAAs

Patients with optimum clinical outcomes (A01, A08) experienced baseline
immune responses to antigens in the tumor material as well as responses to TRP-2,
survivin and SOX-2 (Hunn et al., 2014). The two patients also had the lowest level of
Treg at baseline and one of these also had the lowest level of putative Myeloid-Derived
Suppressor Cells MDSC and high proportion of CD8+. One patient (A08) also had an
unusually high proportions of CD4+ effector cells. Response categorization was based on
the WHO UICC system (Hunn et al., 2014).
A significant correlation of PFS and OS with quantitative expression of MAGE1
and AIM-2 were detected. Patients with overexpression of HER2 and gp100 reached a
relatively long survival (Phuphanich et al., 2012).

4.1.2.4 CD133 Expression
A decrease in or absence of CD133 expression was found in five patients who
underwent a second resection. Patient (#03) experienced recurrent GBM and a decrease
in CD133 expression after vaccination as shown in Figure 4.10. Patient (#08) had
negative expression of CD133. Patient (#10) with a newly diagnosed disease was
negative for CD133 in both the primary and recurrent tumor. Another patient (# 09)
experienced a one-log decrease in CD133 expression. Patient (#19) was negative for
CD133 in the second surgical sample and did not experience a progressive disease
(Phuphanich et al., 2012).
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Figure 4.10 CD133 expression after vaccination with ICT-107 (Phuphanich et al., 2012).

4.1.2.5 The Inhibition of Anti-Tumor Immune Responses by Treg and NK

The GAA-DC trial have been encountered regulatory T cell or NK cell
populations that inhibited anti-tumor immune responses. NK cells activated populations
CD3-, CD16+, CD25+ were found to be significantly increased in the peripheral blood of
patients received GAA-DC. A remarkable independent association between Treg cell
ratios (post/pre-DC vaccination) and overall survival was also reported as shown in table
4.6. The inhibition of Treg and activated NK cells in GBM patients following DC
vaccination was accompanied by observed extended survival. Based on these findings.
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Treg ratio post/pre-DC vaccination may be considered as prognostic biomarkers
for OS in GBM patients (Prins et al., 2013).
Table 4.6 Stratified Cox proportional hazards model for survival with clinical endpoints
and immune monitoring ratios (Prins et al., 2013).

4.1.2.6 The Effect of TMZ + RT Treatment Strategy on Immune Response
TMZ + RT treatment strategy was reported to selectively reduce CD4+ T cells
which may result in the reduction of their negative effects on immune therapy. TMZ was
also reported to cause depletion of CD4+CD25+ T-cell subsets (Su et al., 2004). The
identified Treg cells suppress T-cell responses and the depletion of these cells has
resulted in a significant enhancement of CD8+ T-cell immunity in animal models
(Sakaguchi et al., 2001; Mischo Kursar et al., n.d.).
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4.1.2.7 DC Migration to the Draining Lymph Nodes

A recent study showed that pre-conditioning the vaccine site with
a potent recall antigen such as tetanus/diphtheria (Td) toxoid has been resulted in a
significant enhancement of the lymph node homing, DC migration bilaterally, and
improved OS. There was a significant accumulation of injected DCs in vaccine site
draining lymph nodes (VDLNs) in patients who received Td in contrast with patients who
received un-pulsed DCs as shown in Figure 4.11 (a). Moreover, patients received Td
achieved a significant increase in both PFS as shown in figure 4.11 (b) and OS as shown
in figure 4.11 (c) in contrast with the other group of patients. These findings suggest that
DC migration should be considered as a predictive biomarker for DC-base vaccination
studies as well as other immunotherapy studies (Mitchell et al., 2015).

Figure 4.11 Td pre-conditioning enhances DC migration to VDLNs and increase OS and
PFS (Mitchell et al., 2015).

59
4.2

Data Analysis and Findings

3DWLHQWV¶LQIRUPDWLRQWKHLQFOXVLRQFULWHULDSUHDQGSRVWYDFFLQDWLRQWUHDWPHQW
strategies, and clinical outcomes (OS and PFS) in published clinical trials are shown in
table 4.7.Independent samples t-tests have been used to compare the means of OS and
PFS values of independent sample groups of GBM patients. Moreover, ANOVA test has
been performed to compare the means of OS and PFS values of two or more independent
sample groups of GBM patients.
The first independent samples t-test has been performed to determine the presence
of a statistically significant difference of OS and PFS values at 95% confidence level (D
= 0.05) between two groups of GBM patients. The first group have received DC based
vaccination pulsed with specific antigens (SA) with concomitant or post vaccination
TMZ (n=22 for comparing OS and PFS). The sources of SA antigens include the
synthetic class I peptides (AIM-2, MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2) on
21 patients or the synthetic peptides (TRP-2, gp100, her-2/neu, and survivin) on six
patients. The second group of GBM patients received DC based vaccination loaded with
tumor material antigens (TM) and concomitant or post vaccination TMZ (n=78 for OS
and n= 69 for PFS). The sources of TM antigens include autologous tumor or glioma
cells. The null hypothesis is H0: µ SA = µ TM and the alternative hypothesis is H1: µ SA >
µ TM.Test results showed that with 95% confidence level the mean of the OS and PFS
values for the group of patients who received DC based vaccination pulsed with specific
antigens with concomitant or post vaccination TMZ (SA) is higher than the mean of OS
and PFS values of the group of patients who received DC--Vaccination loaded with
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tumor material antigens and concomitant or post vaccination TMZ (TM) (p= 0.006 and
0.002 respectively).

PreVaccination
TMZ

Concomitant
or postvaccination
TMZ

Age
(years)

A01

Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material
Tumor
Material

Nil

55

Nil

TMZ (2
cycles)
Nil

Nil

A02
A03
A04
A05
A06
A07
A08
A09
A10
A11
A12
A13
A14
A15
A16
A17
A18

OS
(months)

PFS
(months)

70 %

12

-

71

70%

2

-

Nil

25

70%

4

-

Nil

Nil

52

70%

5

-

Nil

44

70%

18

-

Nil

TMZ (6
cycles)
Nil

66

70%

9

-

Nil

TMZ

47

70%

15

-

Nil

TMZ

60

70%

11

-

Nil

TMZ (2
cycles)
TMZ (6
cycles)
TMZ (4
cycles)
TMZ (4
cycles)
TMZ (4
cycles)
TMZ (6
cycles)
TMZ (2
cycles)
TMZ (3
cycles)
TMZ (2
cycles)
TMZ (2
cycles)

55

70%

5

-

39

80%

40

31.5

36

%80

7

5

57

80%

7

2

39

70%

10

6

40

70%

14

12.3

30

100%

7.8

3

35

80%

6

5.3

52

70%

7.8

2

65

70%

10.5

3.5

TMZ (6
cycles)
TMZ (6
cycles)
TMZ (6
cycles)
TMZ (6
cycles)
TMZ (6
cycles)
TMZ (4
cycles)
TMZ (6
cycles)
TMZ (6
cycles)
TMZ (6
cycles)

KPS

Walker et al., 2008

Antigen
Source

Hunn et al., 2014

Patient

References

Table 4.7 3DWLHQWV¶LQIRUPDWLRQ.)6VWDWXVDQWLJHQVRXUFHVWUHDWPHQWVWUDWHJLes, OS,
and PFS values.
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PreVaccination
TMZ

Concomitant
or postvaccination
TMZ

Age
(years)

KPS

OS
(months)

PFS
(months)

A19

Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Tumor
material
Tumor
material
Tumor
material
Tumor
material

TMZ + RT

TMZ

64

100%

28.6

11.5

TMZ + RT

TMZ

46

90%

60.95

60.95

TMZ + RT

TMZ

56

100%

66.51

66.51

TMZ + RT

TMZ

61

90%

60.1

60.1

TMZ + RT

TMZ

51

90%

19.53

6.87

TMZ + RT

TMZ

47

90%

53.03

15.98

TMZ + RT

TMZ

53

905

25.91

12.62

TMZ + RT

TMZ

65

90%

22.55

8.25

TMZ + RT

TMZ

60

90%

38.37

29

TMZ + RT

TMZ

44

80%

49.38

49.38

TMZ + RT

TMZ

34

90%

48.66

48.66

TMZ + RT

TMZ

63

60%

32.42

17.72

TMZ + RT

TMZ

79

70%

15.98

11.28

TMZ + RT

TMZ

52

90%

33.99

8.88

TMZ + RT

TMZ

48

80%

47.64

47.64

TMZ + RT

TMZ

62

90%

41.82

7.27

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

A20
A21
A22
A23
A24
A25
A26
A27
A28
A29
A30
A31
A32
A33
A34
A35
A36
A37
A38

Phuphanich et al., 2012

Antigen
Source

Prins et al., 2013

Patient

References
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Patient

Antigen
Source

PreVaccination
TMZ

Concomitant
or postvaccination
TMZ

Age
(years)

KPS

OS
(months)

PFS
(months)

A39

Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

905

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

A40
A41
A42
A43
A44
A45
A46
A47
A48
A49
A50
A51
A52
A53
A54
A55
A56
A57
A58

References
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Antigen
Source

PreVaccination
TMZ

Concomitant
or postvaccination
TMZ

Age
(years)

KPS

OS
(months)

PFS
(months)

A59

Tumor
material
Tumor
material
Tumor
material
Tumor
material
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Specific
Antigens
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

905

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

49

90%

34.4

18.1

TMZ + RT

TMZ

44

80%

14.5

9.6

TMZ + RT

TMZ

44

80%

14.5

9.6

TMZ + RT

TMZ

44

80%

14.5

9.6

TMZ + RT

TMZ

44

80%

14.5

9.6

TMZ + RT

TMZ

44

80%

14.5

9.6

TMZ + RT

TMZ

44

80%

14.5

9.6

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

A60
A61
A62
A63
A64
A65
A66
A67
A68
A69
A70
A71
A72
A73
A74
A75
A76
A77
A78

Akasaki et al., 2016

Patient

References
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Patient

Antigen
Source

PreVaccination
TMZ

Concomitant
or postvaccination
TMZ

Age
(years)

A79

Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material
Tumor
material

Nil

TMZ

54.6

Nil

TMZ

Nil

A80
A81
A82
A83
A84
A85
A86
A87
A88
A89
A90
A91
A92
A93
A94
A95
A96
A97
A98
A99
A100

KPS

OS
(months)

PFS
(months)

50 %

30.5

18.3

54.6

50 %

30.5

18.3

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

30.5

18.3

Nil

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

TMZ

TMZ

54.6

50 %

18

10.3

References
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There is a statistically significant difference of the means of OS and PFS values between
the two groups. DC vaccine pulsed with specific antigen that were found to be
overexpressed on tumor cells of patients achieved more beneficial clinical outcome than
DC vaccines loaded with tumor material.
ANOVA test has been performed to compare the means of OS and PFS values of
the two groups of GBM patients as shown in figure 4.12 and figure 4.13.

Interval Plot of OS (months) vs Antigen Source
95% CI for the Mean

40

OS (months)

35

30

25

Specific Antigens

Tumor Material

Antigen Source

Figure 4.12 The difference in the means of OS values between two groups of GBM
patients.
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Interval Plot of PFS (months) vs Antigen Source
95% CI for the Mean

30

PFS (months)

25

20

15

Specific Antigens

Tumor Material

Antigen Source

Figure 4.13 The difference in the means of PFS values between two groups of GBM
patients.
The second independent samples t-test has been performed to determine the
presence of a statistically significant difference of OS and PFS values at 95% confidence
level (D = 0.05) between two groups of GBM patients. The first group have received DC
vaccine + concomitant or post vaccination TMZ and did not receive pre-vaccination TMZ
(Nil) (n=31 for OS and n= 22 for PFS). The second group of GBM patients received prevaccination TMZ + DC vaccine + concomitant or post-vaccination TMZ (TMZ) (n= 19
for OS and PFS). The null hypothesis is H0: µ Nil = µ TMZ and the alternative hypothesis is
H1: µ Nil > µ TMZ.
Test results showed that with 95% confidence level (D=.05), the means of the OS
and PFS values for the group of patients who received DC vaccine + concomitant or post
vaccination TMZ and did not receive pre-vaccination TMZ (Nil) is higher than the mean
of OS and PFS values of the group of patients who received pre-vaccination TMZ + DC
vaccine+ concomitant or post-vaccination TMZ (P-Value = 0.001 and 0.000
respectively). There is a statistically significant difference of the means of OS and PFS
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values between the two groups. Our result suggested that receiving pre vaccination TMZ
had been resulted in less beneficial clinical outcomes.
ANOVA test has been performed to compare the means of OS and PFS values of
the two groups of GBM patients as shown in figure 4.14.

Interval Plot of OS (months) vs Pre-Vaccination TMZ
95% CI for the Mean

40

OS (months)

35
30
25
20
15
10
Nil

TMZ

TMZ + RT

Pre-Vaccination TMZ

Figure 4.14 The difference in the means of OS values between different groups of GBM
patients.

The third independent samples t-test has been performed to determine the
presence of a statistically significant difference of OS values at 95% confidence level (D
= 0.05) between two groups of GBM patients. The first group received pre-vaccination
TMZ + RT + DC vaccine + concomitant or post-vaccination TMZ (TMZ+RT, n=50).
The second group of GBM patients DC vaccine + concomitant or post vaccination TMZ
and did not receive pre-vaccination therapy (Nil) (n=31). The null hypothesis is H0: µ
TMZ+RT =

µ Nil and the alternative hypothesis is H1: µ TMZ+RT > µ Nil.
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Test results showed that with 95% confidence level (D=0.05), the mean of the OS
values for the group of patients who received pre-vaccination TMZ + RT + DC vaccine +
concomitant or post-vaccination TMZ (TMZ+RT) is higher than the mean of OS values
for the group of patients who received DC vaccine + concomitant or post vaccination
TMZ and did not receive pre-vaccination therapy (Nil) (P-Value = 0.000). There is a
statistically significant difference of the means of OS values between the two groups.
Receiving pre vaccination TMZ+RT achieved relatively more OS than receiving pre
vaccination Nil as shown in figure 4.14.
The fourth independent samples t-test has been performed to determine the
presence of a statistically significant difference of PFS values at 95% confidence level (D
= 0.05) between two groups of GBM patients. The first group received pre-vaccination
TMZ + RT + DC vaccine + concomitant or post-vaccination TMZ (TMZ+RT, n=50).
The second group of GBM patients received DC vaccine + concomitant or post
vaccination TMZ and did not receive pre-vaccination therapy (Nil, n=22). The null
hypothesis is H0: µ TMZ+RT = µ Nil and the alternative hypothesis is H1: µ TMZ+RT > µ Nil.
Test results showed that with 95% confidence level (D=.05), the mean of the OS
values for the group of patients who received pre-vaccination TMZ + RT + DC vaccine +
concomitant or post-vaccination TMZ is not higher than the mean of OS values for the
group of patients who received DC vaccine + concomitant or post vaccination TMZ and
did not receive pre-vaccination therapy (Nil) (P-Value = 0.194). There is no statistically
significant difference of the means of the PFS values between the two groups.
ANOVA test has been performed to compare the means of PFS values of the two
groups of GBM patients as shown in figure 4.15.
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Interval Plot of PFS (months) vs Pre-Vaccination TMZ
95% CI for the Mean

25

PFS (months)

20

15

10

5
Nil

TMZ

TMZ + RT

Pre-Vaccination TMZ

Figure 4.15 The difference in the means of the PFS values between different groups of
GBM patients involved in different treatment strategies.

ANOVA test has been performed with 95% confidence level (D= 0.05) to
determine the presence of a statistically significant difference between the means of OS
and PFS values of two groups of GBM patients. The first group includes patients who
received DC based vaccination + concomitant or post-vaccination TMZ with or without
RT (n=100 for OS values and n=91 for PFS values). The second group includes patients
who received TMZ+RT with no DC vaccine (n=287). The null hypothesis is H0: µ1= µ2
DQGWKHDOWHUQDWLYHK\SRWKHVLVLV+
The test results showed that there is a statistical significant difference between the
means of OS (P=0.00) and PFS values (P=0.00) of the two groups of GBM patients as
shown in figure 4.16 and figure 4.17.
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Interval Plot of OS (DC+TMZ) , OS (TMZ+RT)
95% CI for the Mean

30.0
27.5

Data

25.0
22.5
20.0
17.5
15.0

OS (DC+TMZ) W/WO RT

OS (TMZ+RT)

Figure 4.16 The difference of means of OS values between two groups of GBM patients.
Interval Plot of PFS (DC+TMZ), PFS(TMZ+RT)
95% CI for the Mean

20.0

17.5

Data

15.0

12.5

10.0

7.5

5.0
PFS (DC+TMZ) W/WO RT

PFS(TMZ+RT)

Figure 4.17 The difference of means of PFS values between two groups of GBM
patients.

4.3

Summary

This chapter has presented the collected data, data analysis techniques, test results
and findings of this research.
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CHAPTER 5. DISCUSSION, CONCLUSION AND RECOMMENDATIONS

This chapter disFXVVHVWKH)'$¶VWKLQNLQJRIFDQFHUYDFFLQHVWKHFRQFOXVLRQ and
the results of this study and the recommendations for the future studies.

5.1

5.1.1

Discussion

)'$¶V&XUUHQW7KLQNLQJRQ,QYHVWLJDWLRQDO6WXGLHVRI&DQFHU9DFFLQHV

Chemotherapy and radiotherapy are immunosuppressive and may minimize the
potential responsiveness to the cancer vaccine being tested on patients with recurrent
diseases. The immunomodulatory effects of concomitant treatments such as
chemotherapies should be justified and considered in the clinical trial design.
Anti-tumor immune response generally requires 2-3 months to be detected and
initiate the effectiveness of a cancer vaccine. Cancer vaccines are better to be tested in
patients with no evidence of residual disease to provide enough time for the cancer
vaccine to initiate an immune response that could be measured. As a result, patients may
experience early progression followed by subsequent response, which should be
considered in the design of clinical trials.
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The disadvantage of the clinical development of cancer vaccines is that it may
require more patients and time than developing conventional therapies. This approach
may not be able to provide interpretable evidence of efficacy because of recruiting
patients with heterogeneous tumor types and stages. The preparation of vaccines using
autologous patient materials is another challenge because of the differences in each
patient and tumor histology. Heterogeneity of the patient population should be considered
before selecting the patient population (Guidance for Industry Clinical Considerations for
Therapeutic Cancer Vaccines, 2011).
5.1.2

)'$¶V5HFRPPHQGDWLRQV for Monitoring the Immune Response

Assays that measure the immune responses are crucial for the detection of antitumor responses that were developed after DC vaccine. At least two immunological
assays should be used to determine the targeted anti-tumor response. Assay conditions,
sensitivity and specificity of the assay, positive and negative controls, end points for the
assessment of results, and the statistical analytical methods should be considered as
important parameters and identified before starting clinical trials (Guidance for Industry
Clinical Considerations for Therapeutic Cancer Vaccines, 2011).

5.2

Conclusion and Research Results

Current treatment options including surgery, radiotherapy, and temozolomide
chemotherapy are associated with limited clinical benefits. The median OS reached by
GBM patients was approximately 12 months only after being treated with radiotherapy
alone without temozolomide. However, the median OS has been estimated as 14.6
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months in patients who received the combined treatment of radiotherapy and
chemotherapy with temozolomide.
There is a great need for an optimized therapy for the treatment of GBM. Dendritic
Cells DCs are the most potent antigen presenting APCs in the immune system. DCs have
the ability to capture and process neoantigens; which are formed and released by
oncogenesis. DCs present the captured antigens on Histocompatibility Complex I and II
(MHCI and MHCII) molecules to stimulate the native T cells and induce primary
immune responses and peripheral immunological tolerance. After T cell responses
against the cancer-specific antigens are primed and activated, T cells infiltrate the tumor
bed, specifically recognize, bind to, and kill their target cancer cell. Clinical trials showed
that treating GBM patients with surgery, TMZ, and Dendritic Cell DC vaccines was safe
and achieved meaningful clinical outcomes. Different clinical outcomes and immune
responses were associated with DC- based vaccination therapy. The sources of antigen
that have been used in DC immunotherapy include synthetic class I peptides AIM-2,
MAGE1, TRP-2, gp100, HER2/neu, and IL-13Ra2, synthetic peptides TRP-2, gp100,
her-2/neu, and surviving, and autologous tumor or glioma cells.
Our study showed that the treatment strategy of DC-based vaccination combined
with chemotherapy with or without RT has proved to achieve substantial clinical benefits.
The median of OS and PFS of GBM patients who received DC vaccines combined with
conventional treatments were 27.5 months and 17.5 months respectively. However, the
median of OS and PFS of GBM patients who received conventional treatments of
chemotherapy with TMZ and radiation therapy were 14.6 months and 6.9 months
respectively.
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This research also has showed a proof of evidence that clinical outcomes of
different DC- based vaccination therapy for the treatment of GBM patients vary based on
the sources of antigens and different pre-vaccination strategies. DC vaccines were loaded
with Tumor Material, pulsed with different Tumor Associated Antigens TAAs, and
combined with different pre and post vaccination treatment strategies. These variables
resulted in different clinical outcomes and different levels of immune responses. DC
vaccine pulsed with specific synthetic antigens that were found to be expressed in tumor
cells of GBM patients achieved more beneficial clinical outcome than DC vaccines
loaded with tumor material. Receiving pre vaccination TMZ has resulted in less
beneficial clinical outcomes (OS and PFS) than receiving DC vaccine without prevaccination TMZ. Receiving pre vaccination TMZ+RT achieved relatively longer OS
than receiving DC vaccine without pre-vaccination TMZ. However, there was no
evidence of a meaningful improvement of PFS with the pre-vaccination treatment
strategy of TMZ+RT.
Assays that measure the immune responses are crucial for the detection of antitumor responses that were developed after vaccination with DCs. Different tumor
VSHFLPHQV¶ analysis and assays such as the immunohistochemical analysis and CTL
assays have been performed in clinical trials to determine immune responses that were
strongly related to the relatively long OS and PFS. There were many immune responses
that were related to the most beneficial clinical outcomes; which can be considered as
prognostic biomarkers of GBM. Patients who developed post-vaccination peripheral
tumor-specific CTL activity have reached longer survival and did not experience
progressive disease in contrast with patients who did not develop post-vaccination CTL.
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Robust infiltration of CD3+ and tumor-infiltrating lymphocytes (TIL) such as CD8+,
CD45RO+ memory T cells, and CD4+ helper T cells in post-vaccination specimens was
found to be related to long OS. Antigen-specific CTL responses against specific antigens
such as WT-1, gp-100, MAGE-A3, TRP-2, survivin and SOX-2 were also found to be
related to a relatively long OS after vaccination with DC-based vaccination treatment.
Lower expression of transforming growth factor-ȕ 7*)ȕLQ*%0SDWLHQWVZDVfound
to be related to long OS. low level of Treg and putative Myeloid-Derived Suppressor
Cells MDSC at baseline was found to be related to beneficial clinical outcomes.
Moreover, the enhancement of DCs migration to the draining lymph nodes was also
associated with a significant increase in both PFS and OS. Treg ratio post/pre-DC
vaccination, DC migration to the draining lymph nodes, and the expression of TGFȕ
MDSC, and CD133 should be considered as prognostic biomarkers for DC-based
vaccination studies.
The expression of the stem cell marker CD133 and specific Tumor Associated
Antigens TAAs such as WT-1, gp-100, and MAGE-A3 on GBM cells was found to result
in resistance to RT and chemotherapy and significant increase in tumor aggressiveness.
Cytomegalovirus phosphoprotein 65pp65 HCMV was also found to be expressed in more
than 90% of GBM specimens in contrast with normal brain. CD133, WT-1, gp-100,
MAGE-A3, and HCMV viral proteins may be used as tumor-specific targets.

5.3

Future Recommendations

Future studies should investigate the rate-limiting steps that negatively affect the
production of antitumor immune responses. Overcoming this problem will enhance the
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effectiveness of DC vaccines and other immunotherapies. As we previously mentioned in
the data analysis section, loading DCs with specific antigens that were found to be
overexpressed in GBM cells has achieved substantial clinical outcomes. There is a great
need to identify a set of antigens that is expressed in all GBM patients. Targeting those
antigens will introduce an optimized DC-based vaccination therapy that will successfully
initiate specific immune responses and eradicate GBM cells.

-*450'3&'&3&/$&4
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